(www.interscience.wiley.com) DOI 10.1002/jrs.2453

Received: 13 March 2009 **Accepted: 19 July 2009** Published online in Wiley Interscience: 9 September 2009

Insights into phase stability of anhydrous/hydrate systems: a Raman-based methodology

Mariela M. Nolasco,a[∗] Ana M. Amado^b and Paulo J. A. Ribeiro-Claro^a

FT-Raman spectroscopy turns out to be a powerful technique to evaluate the amount of polymorphic and pseudopolymorphic forms in crystalline samples – which is particularly relevant in pharmaceutical sciences. This paper presents a methodology that allows successful quantitative evaluation of the solid-state hydration and dehydration processes, using FT-Raman spectroscopy. All the steps required for a reliable evaluation of the hydration/dehydration process are illustrated for the caffeine system, a particularly challenging system presenting limited spectral differences between the pseudopolymorphs. The hydration process of caffeine was found to occur in a single-step process with a half-life time of *ca* **13 h, while the dehydration occurs through a two-step mechanism. The critical relative humidity was found to be at** *ca* **81 and 42% for anhydrous and hydrate caffeine forms, respectively. Copyright c 2009 John Wiley & Sons, Ltd.**

Supporting information may be found in the online version of this article.

Keywords: Raman spectroscopy; hydration/dehydration; kinetics; phase stability; caffeine

Introduction

It has long been known that pharmaceutical solids can exist inmore than one solid-state crystal form, $[1]$ which can have significantly different pharmaceutical properties, such as solubility, dissolution rate and bioavailability.^[2-5] In addition to polymorphs,^[6,7] other examples of possible solid states are solvates and hydrates.[8]

Different techniques ranging from thermal methods to spectroscopic tools (nuclear magnetic resonance, X-ray diffraction and vibrational spectroscopy) can be applied to monitor pseudopolymorphic transitions.^[9-14] In the last few years, the investigation of pharmaceutical compounds by means of Raman spectroscopy has attracted much interest, and some exhaustive reports $[15-17]$ have pointed out the pharmaceutical applications of Raman spectroscopy. This technique, which provides an excellent method for probing solid-state hydrogen-bonding interactions between molecules (including polymorphs and solvates^[9,10,15,18-23]), is more often associated with qualitative analysis. However, the application of Raman spectroscopy to monitor the solid-phase composition during polymorphic and pseudopolymorphic phase transitions has been described in recent publications.^[24-35]

It has been reported that approximately one-third of pharmaceutical solids are capable of forming a hydrate form,^[36] depending on the environmental conditions (temperature and vapor pressure).^[37] As the hydration state may affect the physical and chemical properties of the pharmaceutical product, $[4,5]$ it is important to know the response of pharmaceutical solids to different environments of storage, namely humidity and temperature conditions, evaluating therefore the solid-state interconversion of such hydrates with their anhydrous forms that dictate the stability of a solid phase.

In order to accomplish this purpose, a Raman spectroscopy methodology is presented and applied for caffeine – used as a model drug. This methodology was found to yield reliable kinetic data for systems that present large spectral changes between hydrate and anhydrous forms, such as theophylline^[27] and niclosamide.[29] The applicability of the methodology in systems with less evident changes is well illustrated in this study with caffeine.

Caffeine (1,3,7-trimethylpurine-2,6-dione; hereafter called CA, Fig. 1) is a methylated xanthine derivative that naturally occur in food products such as tea, coffee and chocolate and is one example of the many drugs sensitive to polymorphic and pseudopolymorphic transformations.[38 – 45] This compound finds a variety of medical applications, being routinely prescribed, for instance, as a central nervous system stimulant^[46] and presents beneficial effects in preventing Parkinson and Alzheimer diseases.^[47-49] CA is also known to cause diuresis,^[50] and their administration seems to protect mice against whole-body lethal dose of *γ*-irradiation.^[51]

The solid-sate properties of CA have been widely investigated; it is known to crystallize into different crystalline states, namely as one crystalline nonstoichiometric hydrate,^[40,52,53] hereafter named as CAh, and a pair of anhydrous *α*- and *β*polymorphs.[40,52,54 – 58] The anhydrous *β*-form, hereafter named as CAa (anhydrous CA), is stable at room temperature, whereas the *α*-form only occurs at higher temperatures.^[44,45,56,59]

The present paper has been organized as follows. Firstly, the methodology applied is described. Secondly, the results

[∗] *Correspondence to: Mariela M. Nolasco, CICECO, Chemistry Department, University of Aveiro, P-3810-193 Aveiro, Portugal. E-mail: mnolasco@ua.pt*

a *CICECO, Chemistry Department, University of Aveiro, P-3810-193 Aveiro, Portugal*

b *Química-Física Molecular, Chemistry Department, FCTUC, University of Coimbra, P-3004-535 Coimbra, Portugal*

10974555, 2010, 3, Downloaded from https://analyticalsciencejournals

$$
\alpha_{\rm h}(t) = I_{\rm Xh} \big/ [I_{\rm Xh} + (\delta_{\rm Xh}/\delta_{\rm Xa}) I_{\rm Xa}] \tag{4}
$$

and

of time.

$$
\alpha_{a}(t) = I_{\text{Xa}} \big/ [I_{\text{Xa}} + (\delta_{\text{Xa}} / \delta_{\text{Xh}}) I_{\text{Xh}}] \tag{5}
$$

respectively. By definition, $\alpha_h + \alpha_a = 1$.

a given temperature) can be determined as

hydrate forms, respectively.

*I*Xa

 $\frac{I_{\text{Xa}}}{I_{\text{Xh}}} = \frac{\delta_{\text{Xa}}}{\delta_{\text{Xh}}} \times \frac{\chi_{\text{Xa}}}{\chi_{\text{Xh}}}$

Determination of kinetic parameters

One crucial step in any kinetic study is finding the mechanism for the rate-determining reaction step that gives the best description of the studied process, and ultimately allows calculating meaningful kinetic parameters. In this context, once the fractional of conversion (α_h and α_a) has been obtained, a set of kinetics parameters concerning the hydration and dehydration processes can be obtained by fitting different models to the data, which allow

Figure 1. Schematic representation of caffeine and atom numbering used in the text.

obtained for the CA system are presented and discussed in four main sections, concerning (1) the selection of the most useful spectral regions; (2) the calibration procedure; (3) the underlying mechanisms and (4) the critical relative humidity (RH) conditions for both hydration and dehydration processes of CA forms.

Methodology

The Raman spectroscopy methodology here presented is based on the vibrational structural differences observed in most of hydrate/anhydrous systems as a result of the changes in intermolecular contacts. The different spectral Raman features (peak positions and intensities) observed in the spectra of distinct solid-sate forms are the key factors that allow monitoring the process during the phase transition.

Water, being a component of the atmosphere which considerably varies from country to country and day to day, is the most critical parameter when substances may transform to hydrates under normal storage conditions. As water will be absorbed and desorbed with temperature and moisture changes, an experimental methodology that accounts for these factors is of utmost importance.

Consider a hygroscopic pharmaceutical anhydrous compound, Xa, that display facile conversion to a hydrate form, Xh, by uptake of moisture into a solid dosage form upon equilibration with the ambient environment. Monitoring the amount of Xa and Xh forms at different RH and temperature conditions (see below, sample treatment) allows, by using this methodology, the investigation of hydration and dehydration kinetics of pharmaceutical compounds at various conditions of humidity and temperature. Additionally, the possible mechanisms underlying the hydration and dehydration processes of CA forms, as well as the critical RH conditions for both processes, can be determined.

Quantification anhydrous/hydrate forms by peak area measurements

In order to use Raman spectroscopy in the quantitative evaluation of Xa and Xh forms, it is firstly necessary to identify the distinct bands due to the different pseudopolymorphic forms intervening in the reaction pathway, i.e. *reactant* and *product*. Among a given pair of bands ascribed to the *reactant* and *product*, there will be a time-dependent intensity transfer during the reaction.

The selected spectral regions, with spectral differences between anhydrous and hydrate, are evaluated for their suitability to be used in the relative quantification of the two forms, Xa and Xh, as a (3)

^a *^α* stands for Xa [→] Xh or Xh [→] Xa degree of conversion; *^k* is the rate constant of the conversion reaction; *^t* is time of exposure to RH conditions or time of storage at a given temperature.

identifying the mechanism underlying both Xa \rightarrow Xh and Xh \rightarrow Xa conversions. Different kinetic models $f(\alpha) = kt$ have been proposed for characterizing the solid-sate reaction mechanisms, such as the present pseudopolymorphic conversions (Table 1).^[62-65] Some examples of hydration and dehydration kinetics studies described by such models can be found in the literature.^[64,66] For example, dehydration of calcium oxalate monohydrate^[67] was shown to follow geometrical contraction models (M6 and M7 kinetic models of Table 1).

Spectral band deconvolution and mathematical data treatment

For the evaluation of band intensity ratios, the integrated band intensities (I_{Xh} and I_{Xh}) can be determined by band-fitting procedures, using two Gaussian or two Lorentzian functions, after performing a linear baseline correction employing three points. For the determination of pseudo-isosbestic points, the procedure described by Girling and Shurvell^[60] and Pemberton and Shurvell^[61] should be considered.

Different standard statistical criteria may be used to determine the aggregate deviation of a set of measured points from the calculated linear relationship. The most usually used are the correlation coefficient (R^2) and the standard error of the slope of the regression line (s_b). Some authors^[62,68] have reported the inadequacies of using *r*-value as the sole determinant of the applicability of a particular kinetic model, particularly for distinguishing between mechanism that yield similar linear correlation coefficients (R^2) . Davies and Pryor^[68] pointed out the advantages of using *s*^b values instead. In this work, the quality of the linear fit obtained for each kinetic model tested (Table 1) is determined by considering both R^2 and s_b values.

Experimental

Materials

CAa was obtained commercially (Sigma-Aldrich) and used without further purification (grain size between 125 and 250 um). Hydrate CA (CAh) was prepared by dissolving CAa in distilled water at 80 $^{\circ}$ C until a supersaturated solution is prepared. When the solution was allowed to slowly cool to room temperature, the crystals that formed were filtered from the mother liquid, allowed to dry at ambient temperature and then gently milled to a fine powder (grain size between 125 and 250 µm). As CAh when exposed to ambient conditions, even for a short time period, tend to undergo partial dehydration, the fine powder was stored in a sealed vessel at 92% RH in the presence of a saturated solution of potassium nitrate.

Sample treatment

In order to monitor the hydration and dehydration kinetics by Raman spectroscopy, different types of experiments were performed. In a first type of experiment, both anhydrous \rightarrow hydrate and hydrate \rightarrow anhydrous phase transitions were induced by defined RH and studied at 22 °C ambient temperature. CAa (commercial powder) and CAh samples (*ca* 0.1 g) were transferred to sealed vessels and exposed, for different time intervals, to the water atmosphere of 100 and 0% RH (without direct contact between the sample and the bulk liquid, Fig. 2), by considering pure water and anhydrous CuSO4, respectively. In a second type of experiment, the dehydration process was promoted by storing the CAh samples at different temperatures (35, 45 and 60 $^\circ$ C) for different time periods, under ambient RH conditions. In both the experiments, after the defined time intervals of exposure, the FT-Raman spectra of the different samples were recorded.

condition. After that period of exposure, the FT-Raman spectra of the different samples were recorded. All experiments were performed at ambient temperature. In order to determine the calibration relationship, physical mixtures of CAh/CAa with known compositions (CAh molar fractions of 0.00, 0.155, 0.165, 0.222, 0.500, 0.751 and 1.00) were

prepared by smoothly mixing the samples in a mortar for 2 min to ensure mixing uniformity. Effects of particle size were examined by manually sieving samples to give particle size ranges between 125 and 250 µm.

FT-Raman spectroscopic experiments

The FT-Raman spectra were recorded on an RFS-100 Bruker FTspectrometer, using a Nd : YAG laser with excitation wavelength of 1064 nm, with laser power set to 300 mW. Each spectrum is the measurement of 100 scans with 2 cm^{-1} resolution. As emphasized in our previous work,^[27] it is apparent that in some experiments the sample temperature can rise significantly due to laser exposure^[70,71] and promote either loss of solvent molecules or polymorphic transformations. For the purpose of evaluating

this effect, a sample of CAh was exposed continuously to 500 mW laser power for approximately 1 h and 40 min, and 20 records of 5 min each were collected. All the FT-Raman spectra reported on this work (using the conditions described above) have been collected in 25 min or less, after which period no spectral changes assignable to sample heating were observed on the exposure of CAh to the laser.

Results and Discussion

Selection of the most useful spectral regions

Figure 3 compares the Raman spectra of CAa and CAh forms in the 100–1800 cm⁻¹ and 2700–3400 cm⁻¹ spectral regions. Selecting a suitable region for quantitative analysis would initially appear difficult since the FT-Raman spectra have very similar patterns, reflecting minor changes in the molecular vibrations due to different packing arrangements of the molecules.

The spectral regions labeled with wavenumbers in Fig. 3 were found to be the most amenable for the present study, according to the criteria defined above: each pair presents a pseudo-isosbestic point and can be described in the spectral deconvolution process by only two single bands, avoiding the 'over-parameterization' errors.

According to our previous study,^[72] these are related to the stretching mode of the oscillators C_8 – H (3070–3150 cm⁻¹) and $CC + CN$ (1270–1310 cm⁻¹). In the remaining regions, only slight intensity changes are observed. The complete vibrational assignment can be found in the reported study.^[72]

Calibration procedure

Figure 4 summarizes the calibration procedure for the stretching mode of the oscillators $C_8 - H(3070-3150 \text{ cm}^{-1})$. Figure 4(a) shows that this spectral region presents an isosbestic point at 3117 cm⁻¹. Figure 4(b) shows the plot of *I_{CAa}*/*I_{CAh}* versus $χ_{CAa}/χ_{CAh}$ used to evaluate the required ratio δ _{CAa}/ δ _{CAh}. This calibration procedure was also made for the 1270–1310 cm^{-1} spectral region, and the results are summarized in Table 2.

The comparison between the FT-Raman spectra of CAa (solid line) and CAh (dashed line) forms in the 1270–1310 and

Figure 3. FT-Raman spectra of CAa and CAh in the 100–1800 cm−¹ and 2700–3400 cm−¹ spectral regions. Some bands showing the most pronounced differences between CA forms are marked.

Figure 4. Calibration procedure. (a) FT-Raman spectra, in the 3070–3150 cm−1, of physical mixtures of CAa and CAh with well-known composition (CAh molar fractions of 0.00, 0.155, 0.165, 0.222, 0.500, 0.751 and 1.00 were used). A pseudo-isosbestic point is observed at 3117 cm−1; (b) plot of *I*_{CAa}/*I*_{CAh} versus χ _{CAa}/ χ _{CAh} (error bars included).

3070–3150 cm−¹ spectral regions, after scaling in order to reflect their relative intrinsic intensities, is shown in Fig. 5.

Mechanisms underlying hydration/dehydration processes of CA forms

The dehydration process of CAh has been studied in detail,^[40-43,52,73,74] but significantly less research has been done on the reverse process, from anhydrous caffeine to hydrate caffeine.[43,74]

Mechanism for the CAa→*CAh process*

The kinetics of anhydrous conversion form CAa to CAh by exposure to water-saturated atmosphere were monitored as described in the experimental section. Figure 6(a) and (b) show the sequential change of the CC + CN stretching mode (1270–1310 cm⁻¹ region) and the plot of the measured fractional of hydration (α_h) as a function of time of exposure to RH $=$ 100% conditions at 22 $^{\circ}$ C. The time-dependent intensities observed in the 3070–3150 cm^{-1} spectral region present a similar behavior.

The steepest increase is observed around *ca* 960 min (16 h), and after 25 h of exposure the anhydrous form was totally transformed to the hydrate (situation referred to in Fig. 6(a) as CAh), which is in accordance with the results of X-ray diffraction and hygroscopicity measurements published by Pirttimäki and Laine.^[43] Larger times of exposure did not give rise to any further observable spectral change.

The fractional of hydration (α_h) measured for the two considered regions were fitted to the different kinetic models listed in Table 1, in order to choose the model giving the best statistical fit. As already emphasized in this work, the most usually used statistical criteria are the correlation coefficient (R^2) and the standard error of the slope of the regression line (s_b). Thus, the quality of the linear fit obtained for the different kinetic models was determined by considering both of them (Table S1, Supporting Information). Table 3 shows the best kinetic results obtained for CAa hydration.

Although the R^2 and s_b values for M9 and M13 kinetic models are somewhat similar (Table 3), M9 was assumed to yield a better description of the overall results (two spectroscopic regions). Within this assumption, it was found that the hydration of CAa follows a *one-step random nucleation process*, described by the Avrami–Erofeev equation of exponent 1/2 with a rate constant of ca (1.14 \pm 0.05) × 10⁻³ min⁻¹. The time required for half-hydration $(t_{1/2})$ was *ca* 750 min (\approx 13 h) with the completion of CAa hydration after *ca* 3030 min (≈51 h).

Although these results are not in accordance with the studies of Pirttimäki and Laine, $[43]$ which suggest that CAa hydration involves two steps with a 50% hydration achieved after 26 h, these discrepancies can be explained by the different history of the CAa samples used. In this work, commercial CAa samples were used, while in the reported study^[43] the CAa samples were obtained by dehydration of CAh samples. This situation can lead to significantly different samples morphologies (e.g. grain size and crystal defects), which can affect the hydration behavior.

Mechanism for the CAh→*CAa process*

The kinetics of the conversion of CAh to CAa by exposure to very low water vapor pressure conditions were monitored. Figure 7(a)

^a In accordance with Ref. [72]; *v* stands for stretching.
^b b and s_h stand for slope and slope standard deviation of the linear regression line, respectively; R² for the correlation coefficient; δ_{CAR} and $\$ for intrinsic intensities of the mode for the CAh and CAa forms, respectively.

Figure 5. Comparison of the FT-Raman spectra of CAa (solid line) and CAh (dashed line) forms in the 1270–1310 cm−¹ and 3070–3150 cm−¹ spectral regions, after scaling in order to reflect their relative intrinsic intensities.

Figure 6. (a) FT-Raman spectra, in the 1270–1310 cm⁻¹ region, of CAa samples as a function of time of exposure to RH = 100% conditions; (b) plot of the fractional of hydration (*α*h, %) as a function of time of exposure to the RH = 100% conditions (22 ◦ C); (c) Fitting of the *α*^h values to the Avrami–Erofeev random nucleation ($n = 0.5$) equation.

and (b) show the sequential change of the C_8 –H stretching mode spectral region (3070–3150 cm⁻¹) and the plot of the measured fractional of dehydration (α_a) as a function of time of exposure to RH $=$ 0% conditions at 22 °C. The time-dependent intensities observed in the 1270–1310 cm−¹ spectral region present a similar behavior.

The CAh dehydration promoted by $RH = 0\%$ conditions is consistent with a two-step process, also suggested by Pirttimäki and Laine.^[43] The first evidences of the CAh \rightarrow CAa conversion are detectable after 2 h (120 min) of exposure to $RH = 0\%$ conditions, with the complete dehydration observed after 24 h (situation referred to in Fig. 7(a) as CAa).

After fitting the α_a data to the different kinetic models (Table S2, Supporting Information), the best kinetics results (Table 4) reveal that, for the two spectroscopic regions, the first step of CAh dehydration can be described by the Avrami–Erofeev equation of exponent 2/3, with a rate constant of *ca* $(5.6 \pm 0.5) \times 10^{-3}$

min−1, which corresponds to a half-life time of *ca* 141 min. For the second step, we can assume that it is best represented by the three-dimensional diffusion mechanism (Jander equation) with a rate constant of *ca* (7.7 \pm 0.1) × 10⁻⁵ min⁻¹.

Griesser and Burger,[42] by applying microscopic and various thermoanalytical techniques, also suggested the same mechanism for CAh dehydration at low water vapor pressure (RH between 0 and 13%), in which it was assumed that water leaves the crystal through the channel structure.^[40,42,74] As their CAh sample preparation was the same as in the present work, this similarity reinforces the idea that the experimental conditions are critical in these studies.

The dehydration of CAh samples was also monitored at 35, 45 and 60 $^{\circ}$ C. Figure 8 shows the plot of the measured fractional of dehydration (α_a), derived from the 3070–3150 cm⁻¹ spectral region, as a function of time of storage at 35, 45 and 60 ◦ C.

^a Kinetic model described in Table 1.

^b Time for half-hydration $f(\alpha)$ is equal to 0.833 and 0.5 for M9 and M13, respectively, using ($\alpha = 0.5$).
^c Time for total hydration (f(α) equal to 3.393 and 0.99999 for M9 and M13, respectively, using $\alpha = 0.999$

Figure 7. (a) FT-Raman spectra, in the 3070–3150 cm⁻¹ region, of CAh samples as a function of time of exposure to RH = 0% conditions; (b) plot of the fractional of dehydration ($\alpha_{\rm a}$, %) as a function of time of exposure to the RH $=$ 0% conditions (22 $^{\circ}$ C).

The general results obtained for the different temperatures are consistent with a two-step process, like the dehydration promoted by RH $= 0\%$ conditions, and after 1440 min (24 h) the CAh dehydration is complete. At 45 and 60 $^{\circ}$ C, the first step of CAh dehydration is too fast to allow a kinetic study with this technique. In fact, the time required to achieve 75% dehydration is of the order of 100, 30 and 5 min at 35, 45 and 60 $^\circ$ C, respectively. In the case of the 35 $^{\circ}$ C experiment, according to the best kinetic results (Table 5 and Table S3, Supporting Information), we can assume that the first step of CAh dehydration is described by zero-order mechanism (Polany–Wigner equation) with a rate constant of *ca* (7*.*15±0*.*74)×10−³ min−1, which corresponds to a half-life time of *ca* 67 min. The second step can be described by random nucleation (Mampel equation) with a rate constant of *ca*. $(4.89 \pm 0.68) \times 10^{-3}$ $min⁻¹$.

Critical RH conditions for hydration/dehydration processes of CA forms

The stability of a solid drug substance in the presence of atmospheric moisture is of concern to the pharmaceutical industry, as it has practical implications for processing and storage.[5] It is sometimes the case that an anhydrous crystal is stable below a certain critical RH but at higher RH it will convert to a crystalline hydrate^[75] and vice versa. As this hydration or dehydration aging phenomena can affect several drug properties, the knowledge of a critical RH of a particular drug is essential to obtain a stable final dosage.

Critical RH for CAa→*CAh process*

The information concerning the critical RH for $CAa \rightarrow CAh$ conversion is scarce, but the occurrence of this phase transition at high humidity has been reported.^[76]

Figure 9(a) shows the Raman spectra, in the 3070–3150 cm⁻¹, obtained for CAa samples stored at different RH values for 1 week at 22 $^\circ$ C. The corresponding plot of the measured fractional of hydration (α_h) as a function of RH values is shown in Fig. 9(b).

Spectral evidences of the presence of CAh form occur only for RH *>*81%,while evidences of the presence of the CAaform completely vanish for RH $>$ 90%. After 1 week at RH $=$ 86% the amount of sorbed water still very low, approximately 23% hydration. These

Table 4. Values of rate constant of dehydration (*k*), standard deviation of the slope (s_b), correlation coefficient ($R²$) and time of half-dehydration (*t*1*/*2) obtained for the best linear fits*f*(*α*), of the first and second step data, considering two different spectral regions (CAh→CAa conversion induced by $RH = 0\%$ conditions)

scribed in Table 1.

^b Time for half-dehydration ($f(\alpha)$ is equal to 0.78 and 0.69 for M12 and M8, respectively, using $\alpha = 0.5$).

Figure 8. Plot of the fractional of dehydration (α_a , %), derived from the 3070–3150 cm⁻¹ spectral region, as a function of time of storage at 35 $^{\circ}$ C (black circle), 45 $^\circ$ C (white circle) and 60 $^\circ$ C (black square).

results indicate that CAa exhibits low hygroscopicity over a wide range of RH conditions and the CAa \rightarrow CAh conversion occurs in a narrow range of RH values, within the 1-week time scale.

Critical RH for CAh→*CAa process*

Concerning the critical RH condition for the CAh \rightarrow CAa conversion, although Griesser and Burger^[42] reported that CAh starts to lose the water of crystallization even at RH $= 61\%$ for temperatures around 25 $^\circ$ C, which is in accordance with our results (Fig. 10), the range of RH values for this conversion is missing.

When stored at RH *>* 61%, CAh shows good stability, whereas with a decrease in humidity it starts to dehydrate. According to our results, while at $RH = 42\%$ the Raman spectrum of CAh already shows the presence of small amounts of CAa, the full dehydration after 1 weak exposure is observed only for $RH = 30\%$.

Conclusions

Raman spectroscopy has proved its sensitivity and suitability for the quantification of anhydrous and hydrate forms in caffeine, a model compound that does not present large spectral differences between the pseudopolymorphs. As illustrated in this study, even the small differences like those exhibited by the FT-Raman spectra of anhydrous and hydrate caffeine can be used in a successful quantitative evaluation of the solid-state forms during hydration and dehydration processes. The methodology described here provides all the steps required to perform such evaluation.

The hydration of CAa was found to be *a one-step random nucleation process,* described by the Avrami–Erofeev equation of exponent 1/2 with a rate constant of *ca* (1*.*14±0*.*05)×10−³ min−1, which corresponds to half-life of *ca* 13 h. On the other hand, the dehydration promoted by $RH = 0\%$ conditions and by different temperatures occurs through a two-step mechanism.

The first step of CAh dehydration (RH $=$ 0%) can be described by the Avrami–Erofeev equation of exponent 3/2, with a rate constant of *ca* (5.6 \pm 0.5) × 10⁻³ min⁻¹, while the second step can be described by the three-dimensional diffusion mechanism (Jander equation) with a rate constant of *ca.* $(7.7 \pm 0.1) \times 10^{-5}$ min−¹ and a half-dehydration time of *ca* 141 min.

Table 5. Values of rate constant of dehydration (*k*), standard deviation of the slope (*s*b), correlation coefficient (*R*2) and time of half-dehydration (*t*1*/*2) obtained for the best linear fits*f*(*α*), of the first and second step data, considering two different spectral regions (CAh→CAa conversion induced by 35 °C temperature conditions)

^a Kinetic model described in Table 2.

^b Time for half-dehydration ($f(\alpha)$ is equal to 0.50 for M13, using $\alpha = 0.5$).

Figure 9. (a) FT-Raman spectra, in the 3070–3150 cm⁻¹ region, of CAa samples stored at different RH values for 1 week (22 °C); (b) plot of the fractional of hydration (*α*h, %) as a function of RH values.

Figure 10. (a) FT-Raman spectra, in the 3070–3150 cm^{−1} region, of CAh samples stored at different RH values for 1 week (22 °C); (b) plot of the fractional of dehydration (α_a , %) as a function of RH values.

The zero-order mechanism (Polany–Wigner equation) can describe the first step of CAh dehydration at 35 $^{\circ}$ C, with a rate constant of *ca* (7*.*¹⁵ [±] ⁰*.*74)×10−³ min−1. The second step can be described by random nucleation (Mampel equation) with a rate constant of *ca* (4.89 \pm 0.68) × 10⁻³ min⁻¹. Additionally, the time required for half-dehydration was *ca* 67 min.

In addition, the phase stability of caffeine system in different RH conditions was probed. The critical RH for anhydrous caffeine was found to be at *ca* 81%, while the critical RH for dehydration is *ca* 42%, values that should be considered during processing and storage conditions.

Acknowledgements

The authors acknowledge financial support from the Portuguese Foundation for Science and Technology (FCT) – *Unidade de Química-Física Molecular* and *Laboratorio Associado CICECO ´* . Mariela M. Nolasco also acknowledges FCT for a research grant – SFRH/BPD/32103/2006.

Supporting information

Supporting information may be found in the online version of this article.

References

- [1] J. Haleblian, W. McCrone, *J. Pharm. Sci.* **1969**, *58*, 911.
- [2] D. A. Snider, W. Addicks, W. Owens, *Adv. Drug Deliv. Rev.* **2004**, *56*, 391.
- [3] L.-F. Huanga, W.-Q. Tong, *Adv. Drug Deliv. Rev.* **2004**, *56*, 321.
- [4] T.-C. Hu, S.-L. Wang, T.-F. Chen, S.-Y. Lin,*J. Pharm.Sci.* **2002**, *91*, 1351.
- [5] R. K. Khankari, D. J. W. Grant, *Thermochim. Acta* **1995**, *248*, 61.
- [6] S. R. Vippagunta, H. G. Brittain, D. J. W. Grant, *Adv. Drug Deliv. Rev.* **2001**, *48*, 3.
- [7] J. Bernstein, R. J. Davey, J. O. Henck,*Angew.Chem.Int.Ed.Engl.***1999**, *38*, 3440.
- [8] A. Nangia, G. R. Desiraju, *Chem. Commun.* **1999**, 605.
- [9] D. E. Bugay, *Adv. Drug Deliv. Rev.* **2001**, *48*, 43.
- [10] M. C. Gamberini, C. Baraldi, A. Tinti, C. Rustichelli, V. Ferioli, G. Gamberini, *J. Mol. Struct.* **2006**, *785*, 216.
- [11] D. A. Roston, M. C. Walters, R. R. Rhinebarger, L. J. Ferro, *J. Pharm. Biomed. Anal.* **1993**, *1993*, 293.
- [12] N. A. T. Nguyen, S. Ghosh, L. A. Gathin, D. J. W. Grant, *J. Pharm. Sci.* **1994**, *83*, 1116.
- [13] K. R. Morris, A. W. Newman, D. E. Bugay, S. A. Ranadive, A. K. Singh, M. Szyper, S. A. Varia, H. G. Brittain, A. T. M. Serajuddin, *Int. J. Pharm.* **1994**, *108*, 195.
- [14] M. Karjalainen, S. Airaksinen, J. Rantanen, J. Aaltonen, J. Yliruusi, *J. Pharm. Biomed. Anal.* **2005**, *39*, 27.
- [15] G. Fini, *J. Raman Spectrosc.* **2004**, *35*, 335.
- [16] S. C. Pînzaru,I. Pavel,N. Leopold,W. Kiefer,*J.RamanSpectrosc.***2004**, *35*, 338.
- [17] T. Vankeirsbilck, A. Vercauteren, W. Baeyens, G. van der Weken, F. Verpoort, G. Vergote, J. P. Remon, *TRAC, Trends Anal. Chem.* **2002**, *21*, 869.
- [18] M. Szelagiewicz, C. Marcolli, S. Cianferani, A. P. Hard, A. Vit, A. Burkhard, M. von Raumer, U. C. Hofmeier, A. Zilian, E. Francotte, R. Schenker, *J. Therm. Anal. Calorim.* **1999**, *57*, 23.
- [19] H. G. Brittain, *J. Pharm. Sci.* **1997**, *86*, 405.
- [20] L. E. O'Brien, P. Timmins, A. C. Williams, P. York, *J. Pharm. Biomed. Anal.* **2004**, *36*, 335.
- [21] D. Pratiwi, J. P. Fawcett, K. C. Gordon, T. Rades, *Eur. J. Pharm. Biopharm.* **2002**, *54*, 337.
- [22] C. Starbuck, A. Spartalis, L. Wai, J. Wang, P. Fernandez, C. M. Lindemann, G. X. Zhou, Z. Ge, *Cryst. Growth Des.* **2002**, *2*, 515.
- [23] D. S. Hausman, R. T. Cambron, A. Sakr, *Int. J. Pharm.* **2005**, *299*, 19.
- [24] S. Airaksinen, P. Luukkonen, A. Jørgensen, M. Karjalainen,
- J. Rantanen, J. Yliruusi, *J. Pharm. Sci.* **2003**, *92*, 516. [25] A. K. Salameh, L. S. Taylor, *J. Pharm. Sci.* **2006**, *95*, 446.
- [26] M. E. Auer, U. J. Griesser, J. Sawatzki, *J. Mol. Struct.* **2003**, *661*(662),
- [27] A. M. Amado, M. M. Nolasco, P. J. A. Ribeiro-Claro, *J. Pharm. Sci.* **2007**, *96*, 1366.
- [28] A. Caillet, P. Puel, G. Fevotte, *Chem. Eng. Process.* **2008**, *47*, 377.
- [29] M. Sardo, A. M. Amado, P. J. A. Ribeiro-Claro, *J. Raman Spectrosc.* **2008**, *39*, 1915.
- [30] A. Caillet, F. Puel, G. Fevotte, *Int. J. Pharm.* **2006**, *307*, 201.
- [31] S. N. C. Roberts, A. C. Williams, I. M. Grimsey, S. W. Booth, *J. Pharm. Biomed. Anal.* **2002**, *28*, 1135.
- [32] A. P. Ayala, H. W. Siesler, S. L. Cuffini, *J. Raman Spectrosc.* **2008**, *39*, 1150.
- [33] T. Ono, J. H. ter Horst, P. J. Jansens, *Cryst. Growth Des.* **2004**, *4*, 465.
- [34] F. Wang, J. A. Wachter, F. J. Antosz, K. A. Berglund, *Org. Proc. Res. Dev.* **2000**, *4*, 391.
- [35] H. Wikström, P. J. Marsac, L. S. Taylor, J. Pharm. Sci. 2005, 94, 209.
- [36] T. L. Threlfall, *Analyst* **1995**, *120*, 2435.
- [37] H. P. Stahl,*TheProblemofDrugInteractionsWithExcipientsinTowards Better Safety of Drugs and Pharmaceutical Products*, Elsevier: New York, **1980**, p 265.
- [38] M. U. A. Ahlqvist, L. S. Taylor, *Int. J. Pharm.* **2002**, *241*, 253.
- [39] A. Jørgensen, J. Rantanen, M. Karjalainen, L. Khriachtchev, E. Ras¨ anen, J. Yliruusi, ¨ *Pharm. Res.* **2002**, *19*, 1285.
- [40] H. G. M. Edwards, E. Lawson, M. de Matas, L. Shields, P. York. J. Chem. *Soc. Perkin Trans. 2* **1997**, 1985.
- [41] M. de Matas, H. G. M. Edwards, E. E. Lawson, L. Shields, P. York, *J. Mol. Struct.* **1998**, *440*, 97.
- [42] U. J. Griesser, A. Burger, *Int. J. Pharm.* **1995**, *120*, 83.
- [43] J. Pirttimäki, E. Laine, *Eur. J. Pharm. Sci.* **1994**, *1*, 203.
- [44] P. Derollez, N. T. Correia, F. Danède, F. Capet, F. Affouard, J. Lefebvre, M. Descamps, *Acta Crystallogr.* **2005**, *B61*, 329.
- [45] M. Epple, H. K. Cammenga, S. M. Sarge, R. Diedrich, V. Balek, *Thermochim. Acta* **1995**, *250*, 29.
- [46] J. Nikolic, G. Bjelakovic, I. Stojanovic, *Mol. Cell. Biochem.* **2003**, *244*, 125.
- [47] A. Ascherio, S. M. Zhang, M. A. Hernán, I. Kawachi, G. A. Colditz, F. E. Speizer, W. C. Willett, *Ann. Neurol.* **2001**, *50*, 56.
- [48] G. W. Ross, R. D. Abbott, H. Petrovitch, D. M. Morens, A. Grandinetti, K. H. Tung, C. M. Tanner, K. H. Masaki, P. L. Blanchette, J. D. Curb, J. S. Popper, L. R. White, *J Am Med Assoc* **2000**, *283*, 2674.
- [49] L. Maia, A. de Mendonça, *Eur. J. Neurol*. **2002**, 9, 377.
- [50] J. B. Thomas, J. H. Yen, M. M. Schantz, B. J. Porter, K. E. Sharpless, *J. Agric. Food Chem.* **2004**, *52*, 3259.
- [51] K. C. George, S. A. Hebbar, S. P. Kale, P. C. Kesavan, *J. Radiol. Prot.* **1999**, *19*, 171.
- [52] H. Bothe, H. K. Cammenga, *Thermochim. Acta* **1980**, *40*, 29.
- [53] D. J. Sutor, *Acta Crystallogr.* **1958**, *11*, 453.
- [54] L. Carlucci, A. Gavezzotti, *Chem. Eur. J.* **2005**, *11*, 271.
- [55] A. Cesaro, G. Starec, ` *J. Phys. Chem. B* **1980**, *84*, 1345.
- [56] M. Descamps, N. T. Correia, P. Derollez, F. Danede, F. Capet, *J. Phys. Chem. B* **2005**, *109*, 16092.
- [57] C. W. Lehmann, F. Stowasser, *Chem. Eur. J.* **2007**, *13*, 2908.
- [58] S. S. Pinto, H. P. Diogo, *J. Chem. Thermodyn.* **2006**, *38*, 1515.
- [59] V. P. Lehto, E. Laine, *Thermochim. Acta* **1998**, *317*, 47.
- [60] R. B. Girling, H. F. A. Shurvell, *Vib. Spectrosc.* **1998**, *18*, 77.
- [61] R. S. Pemberton, H. F. Shurvell, *J. Raman Spectrosc.* **1995**, *26*, 373.
- [62] M. E. Brown, A. K. Galwey, *Thermochim. Acta* **1979**, *29*, 129.
- [63] A. Ortega, *Int. J. Chem. Kinet.* **2002**, *34*, 223.
- [64] S. Vyazovkin, *J. Comp. Chem.* **1997**, *18*, 393.
- [65] A. Khawan, D. R. Flanagan, *J. Phys. Chem. B* **2006**, *110*, 17315.
- [66] V. K. Peterson, D. A. Neumann, R. A. Livingston, *J. Phys. Chem. B* **2005**, *109*, 14449.
- [67] L. Liqing, C. Donghua, *J. Therm. Anal. Calorim.* **2004**, *78*, 283.
- [68] W. H. Davis Jr., W. A. Pryor, *J. Chem. Educ.* **1976**, *53*, 285.
- [69] R. C. Weast, M. J. Astle, W. H. Beyer, *CRC Handbook of Chemistry and Physics a Ready-Reference Book of Chemical and Physical Data*, CRC Press Inc.: Florida, **1983**, p E42.
- [70] J. Johansson, S. Pettersson, L. S. Taylor,*J. Pharm. Biomed.Anal.***2002**, *30*, 1223.
- [71] N. A. Marigheto, E. K. Kemsley, J. Potter, P. S. Belton, R. H. Wilson, *Spectrochim. Acta* **1996**, *A52*, 1571.
- [72] M. M. Nolasco, A. M. Amado, P. J. A. Ribeiro-Claro, *ChemPhysChem* **2006**, *7*, 2150.
- [73] S. R. Byrn, C.-T. Lin, *J. Am. Chem. Soc.* **1976**, *98*, 4004.
- [74] E. Suzuki, K. I. Shirotani, Y. Tsuda, K. Sekiguchi, *Chem. Pharm. Bull.* **1985**, *33*, 5028.
- [75] M. D. Ticehurst, R. A. Storey, C. Watt, *Int. J. Pharm.* **2002**, *247*, 1.
- [76] E. Shefter, T. Highuchi, *J. Pharm. Sci.* **1963**, *52*, 781.

307.